Rotigotine (BioDeep_00000615048)
代谢物信息卡片
6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol
化学式: C19H25NOS (315.165676)
中文名称: 罗替高汀, 罗替戈汀
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O
InChI: InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3
描述信息
N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists
C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist
Rotigotine is a potent dopamine receptor agonist with Ki values of 0.71?nM, 4-15?nM, and 83?nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor. Rotigotine can be used for parkinson's disease (PD) research[1][2][3][4].
同义名列表
数据库引用编号
12 个数据库交叉引用编号
- ChEBI: CHEBI:135351
- ChEBI: CHEBI:184910
- KEGGdrug: D05768
- PubChem: 59227
- PubChem: 57537
- Metlin: METLIN85553
- DrugBank: DB05271
- ChEMBL: CHEMBL1303
- ChEMBL: CHEMBL104383
- CAS: 99755-59-6
- CAS: 92206-54-7
- medchemexpress: HY-75502
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Ameeduzzafar Zafar, Omar Awad Alsaidan, Nabil K Alruwaili, Syed Sarim Imam, Mohd Yasir, Khalid Saad Alharbi, Lubhan Singh, Mohammed Muqtader Ahmed. Formulation of intranasal surface engineered nanostructured lipid carriers of rotigotine: Full factorial design optimization, in vitro characterization, and pharmacokinetic evaluation.
International journal of pharmaceutics.
2022 Nov; 627(?):122232. doi:
10.1016/j.ijpharm.2022.122232. [PMID: 36155794] - Weibo Sun, Qingyong Wang, Tiansong Yang, Chuwen Feng, Yuanyuan Qu, Yan Yang, Chaoran Li, Zhongren Sun, Tetsuya Asakawa. A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, focusing on sleep disturbances and activities of daily living.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.
2022 Oct; 43(10):5821-5837. doi:
10.1007/s10072-022-06159-9. [PMID: 35691972] - Jie Bai, Li-Yuan Xie, Li Yang, Run-Qin Wang, Xuan Chen, Shuang Hu. Reversed lipid micellar hollow-fiber liquid-phase microextraction of rotigotine in rat plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2021 Jul; 1178(?):122583. doi:
10.1016/j.jchromb.2021.122583. [PMID: 34224964] - Shumin Yue, Tian Wang, Yunqi Yang, Yiqian Fan, Lin Zhou, Mingan Li, Fenghua Fu. Lipopolysaccharide/D-galactosamine-induced acute liver injury could be attenuated by dopamine receptor agonist rotigotine via regulating NF-κB signaling pathway.
International immunopharmacology.
2021 Jul; 96(?):107798. doi:
10.1016/j.intimp.2021.107798. [PMID: 34162160] - Ting Li, Tian Wang, Linlin Wang, Rongxia Liu, Leiming Zhang, Rong Zhai, Fenghua Fu. Antinociceptive effects of rotigotine-loaded microspheres and its synergistic interactions with analgesics in inflammatory pain in rats.
European journal of pharmacology.
2021 Jan; 891(?):173693. doi:
10.1016/j.ejphar.2020.173693. [PMID: 33160937] - C Warren Olanow, David G Standaert, Karl Kieburtz, Tacey X Viegas, Randall Moreadith. Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients.
Movement disorders : official journal of the Movement Disorder Society.
2020 06; 35(6):1055-1061. doi:
10.1002/mds.28027. [PMID: 32251552] - Shadab Md, Shahid Karim, Sanggetha R Saker, Ooi A Gie, Lim C Hooi, Phua H Yee, Alvin W C Kang, Chen K Zhe, Ng Ian, Hibah M Aldawsari, Khaled M Hosny, Nabil A Alhakamy. Current Status and Challenges in Rotigotine Delivery.
Current pharmaceutical design.
2020; 26(19):2222-2232. doi:
10.2174/1381612826666200316154300. [PMID: 32175832] - Kazuhiro Muramatsu, Sachiko Chikahisa, Noriyuki Shimizu, Hiroyoshi Séi, Yuichi Inoue. Rotigotine suppresses sleep-related muscle activity augmented by injection of dialysis patients' sera in a mouse model of restless legs syndrome.
Scientific reports.
2019 11; 9(1):16344. doi:
10.1038/s41598-019-52735-z. [PMID: 31704978] - Manuela Contin, Giovanna Lopane, Susan Mohamed, Giovanna Calandra-Buonaura, Sabina Capellari, Patrizia De Massis, Stefania Nassetti, Alessandro Perrone, Roberto Riva, Luisa Sambati, Cesa Scaglione, Pietro Cortelli. Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease.
Parkinsonism & related disorders.
2019 04; 61(?):111-117. doi:
10.1016/j.parkreldis.2018.11.007. [PMID: 30446407] - Jesus Calviño, Monica Guijarro, Secundino Cigarran, Lourdes González-Tabares, Maria-Jesus Sobrido. A note on rotigotine for restless legs syndrome after renal transplantation.
Movement disorders : official journal of the Movement Disorder Society.
2019 01; 34(1):151-152. doi:
10.1002/mds.27574. [PMID: 30653728] - Aaro V Salminen, Richard P Allen, Birgit Högl, Yuichi Inoue, Wolfgang Oertel, John W Winkelman, Claudia Trenkwalder, Cristina Sampaio, Juliane Winkelmann. Reply to: A note on rotigotine for restless legs syndrome after renal transplantation.
Movement disorders : official journal of the Movement Disorder Society.
2019 01; 34(1):152-153. doi:
10.1002/mds.27570. [PMID: 30653726] - Willi Cawello, Marina Braun, Jens-Otto Andreas. Drug Delivery and Transport into the Central Circulation: An Example of Zero-Order In vivo Absorption of Rotigotine from a Transdermal Patch Formulation.
European journal of drug metabolism and pharmacokinetics.
2018 Aug; 43(4):475-481. doi:
10.1007/s13318-018-0460-3. [PMID: 29332198] - Yun Liu, Brian Tomlinson, Jiyuan Guo, Mahnaz Asgharnejad, Lars Bauer, Erwin Surmann, Xiaojuan Guo, Jan-Peer Elshoff. Pharmacokinetics, Tolerability, and Bioequivalence of Two Formulations of Rotigotine in Healthy Chinese Subjects.
Clinical therapeutics.
2018 07; 40(7):1108-1121.e8. doi:
10.1016/j.clinthera.2018.05.009. [PMID: 30098648] - Chunjie Sha, Jiangbin Han, Fengjuan Zhao, Xin Shao, Huijie Yang, Lei Wang, Fei Yu, Wanhui Liu, Youxin Li. Validated LC-MS/MS method for the simultaneous determination of rotigotine and its prodrug in rat plasma and an application to pharmacokinetics and biological conversion in vitro.
Journal of pharmaceutical and biomedical analysis.
2017 Nov; 146(?):24-28. doi:
10.1016/j.jpba.2017.07.018. [PMID: 28843173] - Susan Mohamed, Roberto Riva, Manuela Contin. Novel UHPLC-MS/MS method for the determination of rotigotine in the plasma of patients with Parkinson's disease.
Biomedical chromatography : BMC.
2017 Sep; 31(9):. doi:
10.1002/bmc.3944. [PMID: 28168729] - Siegfried Muhlack, Manuel Kinkel, Lennard Herrman, Thomas Müller. Levodopa, placebo and rotigotine change biomarker levels for oxidative stress.
Neurological research.
2017 May; 39(5):381-386. doi:
10.1080/01616412.2017.1295520. [PMID: 28222651] - Zeyad T Sahli, Jae Jo, Shaker A Mousa, Frank I Tarazi. Clinical management of restless legs syndrome in end-stage renal disease patients.
CNS spectrums.
2017 Feb; 22(1):14-21. doi:
10.1017/s109285291600064x. [PMID: 27702420] - Carlo Rossi, Dario Genovesi, Paolo Marzullo, Assuero Giorgetti, Elena Filidei, Giovanni Umberto Corsini, Ubaldo Bonuccelli, Roberto Ceravolo. Striatal Dopamine Transporter Modulation After Rotigotine: Results From a Pilot Single-Photon Emission Computed Tomography Study in a Group of Early Stage Parkinson Disease Patients.
Clinical neuropharmacology.
2017 Jan; 40(1):34-36. doi:
10.1097/wnf.0000000000000198. [PMID: 27941527] - Yves Dauvilliers, Heike Benes, Markku Partinen, Virpi Rauta, Daniel Rifkin, Elisabeth Dohin, Nadine Goldammer, Erwin Schollmayer, Hanna Schröder, John W Winkelman. Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2016 Sep; 68(3):434-43. doi:
10.1053/j.ajkd.2015.12.027. [PMID: 26851201] - Jonathan Timpka, Ulrika Mundt-Petersen, Per Odin. Continuous dopaminergic stimulation therapy for Parkinson's disease - recent advances.
Current opinion in neurology.
2016 Aug; 29(4):474-9. doi:
10.1097/wco.0000000000000354. [PMID: 27272976] - Luigi Ferini-Strambi, Sara Marelli, Andrea Galbiati. Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome.
Expert opinion on drug metabolism & toxicology.
2016 Aug; 12(8):967-75. doi:
10.1080/17425255.2016.1194393. [PMID: 27224246] - Willi Cawello, Seong Ryul Kim, Marina Braun, Jan-Peer Elshoff, Takeuchi Masahiro, Junji Ikeda, Tomoo Funaki. Pharmacokinetics, safety, and tolerability of rotigotine transdermal system in healthy Japanese and Caucasian subjects following multiple-dose administration.
European journal of drug metabolism and pharmacokinetics.
2016 Aug; 41(4):353-62. doi:
10.1007/s13318-015-0273-6. [PMID: 25773763] - Chaojun Jia, Lijun Luo, Katsuhisa Kurogi, Juming Yu, Chunyang Zhou, Ming-Cheh Liu. Identification of the Human SULT Enzymes Involved in the Metabolism of Rotigotine.
Journal of clinical pharmacology.
2016 06; 56(6):754-60. doi:
10.1002/jcph.658. [PMID: 26465778] - Peter A LeWitt, Werner Poewe, Lawrence W Elmer, Mahnaz Asgharnejad, Babak Boroojerdi, Frank Grieger, Lars Bauer. The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.
Clinical neuropharmacology.
2016 Mar; 39(2):88-93. doi:
10.1097/wnf.0000000000000133. [PMID: 26882318] - Bo-Hyung Kim, Kyung-Sang Yu, In-Jin Jang, Kyoung Soo Lim, Jung-Ryul Kim, Jan-Peer Elshoff, Jens-Otto Andreas, Marina Braun, Willi Cawello. Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers.
Clinical therapeutics.
2015 Apr; 37(4):902-12. doi:
10.1016/j.clinthera.2015.01.013. [PMID: 25791613] - Jan-Peer Elshoff, Willi Cawello, Jens-Otto Andreas, Francois-Xavier Mathy, Marina Braun. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
Drugs.
2015 Apr; 75(5):487-501. doi:
10.1007/s40265-015-0377-y. [PMID: 25795100] - Arturo Benitez, Heather Edens, Jesse Fishman, Kimberly Moran, Mahnaz Asgharnejad. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
Annals of the New York Academy of Sciences.
2014 Nov; 1329(?):45-66. doi:
10.1111/nyas.12508. [PMID: 25145951] - Willi Cawello, Andreas Fichtner, Hilmar Boekens, Marina Braun. Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine.
European journal of drug metabolism and pharmacokinetics.
2014 Sep; 39(3):155-63. doi:
10.1007/s13318-013-0153-x. [PMID: 24052490] - Jan-Peer Elshoff, Willi Cawello, Jens-Otto Andreas, Marina Braun. No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.
Clinical pharmacology in drug development.
2014 05; 3(3):187-93. doi:
10.1002/cpdd.78. [PMID: 27128608] - Richard K Bogan. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
Clinical therapeutics.
2014 Mar; 36(3):436-55. doi:
10.1016/j.clinthera.2014.01.021. [PMID: 24636821] - Willi Cawello, Seong R Kim, Marina Braun, Jan-Peer Elshoff, Junji Ikeda, Tomoo Funaki. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.
Clinical drug investigation.
2014 Feb; 34(2):95-105. doi:
10.1007/s40261-013-0150-5. [PMID: 24178238] - Jan-Peer Elshoff, Lars Timmermann, Miriam Schmid, Christoph Arth, Michael Komenda, Marcus Brunnert, Lars Bauer. Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulations.
Current medical research and opinion.
2013 Dec; 29(12):1657-62. doi:
10.1185/03007995.2013.841666. [PMID: 24006953] - Pedro Emilio Bermejo, María Ascensión Zea, Lucía Alba-Alcántara, Cristina Ruiz-Huete. [Local effects of transdermal treatment with rotigotine].
Revista de neurologia.
2013 Apr; 56(7):359-62. doi:
NULL. [PMID: 23520004] - Stefano de Biase, Giovanni Merlino, Simone Lorenzut, Mariarosaria Valente, Gian Luigi Gigli. ADMET considerations for restless leg syndrome drug treatments.
Expert opinion on drug metabolism & toxicology.
2012 Oct; 8(10):1247-61. doi:
10.1517/17425255.2012.708023. [PMID: 22808933] - Birgit Högl, Wolfgang H Oertel, Erwin Schollmayer, Lars Bauer. Transdermal rotigotine for the perioperative management of restless legs syndrome.
BMC neurology.
2012 Sep; 12(?):106. doi:
10.1186/1471-2377-12-106. [PMID: 23009552] - Jan-Peer Elshoff, Marina Braun, Jens-Otto Andreas, Michelle Middle, Willi Cawello. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies.
Clinical therapeutics.
2012 Apr; 34(4):966-78. doi:
10.1016/j.clinthera.2012.02.008. [PMID: 22401642] - Eva-Maria Hametner, Klaus Seppi, Werner Poewe. Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease.
Clinical interventions in aging.
2012; 7(?):83-8. doi:
10.2147/cia.s11829. [PMID: 22500116] - Willi Cawello, Sascha Ahrweiler, Wladyslaw Sulowicz, Agnieszka Szymczakiewicz-Multanowska, Marina Braun. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function.
British journal of clinical pharmacology.
2012 Jan; 73(1):46-54. doi:
10.1111/j.1365-2125.2011.04053.x. [PMID: 21707699] - E Grünblatt, W J Schmidt, D K A Scheller, P Riederer, M Gerlach. Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats.
Journal of neural transmission (Vienna, Austria : 1996).
2011 Dec; 118(12):1717-25. doi:
10.1007/s00702-010-0552-y. [PMID: 21188436] - Martin R Farlow, Monique Somogyi. Transdermal patches for the treatment of neurologic conditions in elderly patients: a review.
The primary care companion for CNS disorders.
2011; 13(6):. doi:
10.4088/pcc.11r01149. [PMID: 22454804] - Paolo Solla, Antonino Cannas, Francesco Marrosu, Maria Giovanna Marrosu. Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).
Neuropsychiatric disease and treatment.
2010 Sep; 6(?):483-90. doi:
10.2147/ndt.s5190. [PMID: 20856911] - B Boroojerdi, H-M Wolff, M Braun, D K A Scheller. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
Drugs of today (Barcelona, Spain : 1998).
2010 Jul; 46(7):483-505. doi:
10.1358/dot.2010.46.7.1463530. [PMID: 20683503] - Jack J Chen, David M Swope, Khashayar Dashtipour, Kelly E Lyons. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
Pharmacotherapy.
2009 Dec; 29(12):1452-67. doi:
10.1592/phco.29.12.1452. [PMID: 19947805] - K A Stockwell, D Scheller, S Rose, M J Jackson, K Tayarani-Binazir, M M Iravani, L A Smith, C W Olanow, P Jenner. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
Experimental neurology.
2009 Oct; 219(2):533-42. doi:
10.1016/j.expneurol.2009.07.011. [PMID: 19619533] - Willi Cawello, Marina Braun, Hilmar Boekens. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery.
Drug metabolism and disposition: the biological fate of chemicals.
2009 Oct; 37(10):2055-60. doi:
10.1124/dmd.109.027383. [PMID: 19608695] - Marina Braun, Jan-Peer Elshoff, Jens-Otto Andreas, Louise Ischen Müller, Rolf Horstmann. Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive.
British journal of clinical pharmacology.
2009 Sep; 68(3):386-94. doi:
10.1111/j.1365-2125.2009.03468.x. [PMID: 19740396] - Bao-Lin Chu, Jin-Ming Lin, Zhihua Wang, Baoyuan Guo. Enantiospecific binding of Rotigotine and its antipode to serum albumins: Investigation of binding constants and binding sites by partial-filling ACE.
Electrophoresis.
2009 Aug; 30(16):2845-52. doi:
10.1002/elps.200800521. [PMID: 19691049] - Andreas Wentrup, Wolfgang H Oertel, Richard Dodel. Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.
Drug design, development and therapy.
2009 Feb; 2(?):245-54. doi:
10.2147/dddt.s3102. [PMID: 19920911] - Muhammad M Nashatizadeh, Kelly E Lyons, Rajesh Pahwa. A review of ropinirole prolonged release in Parkinson's disease.
Clinical interventions in aging.
2009; 4(?):179-86. doi:
10.2147/cia.s3358. [PMID: 19503779] - Dieter Scheller, Nick Dürmüller, Paul Moser, Roger D Porsolt. Continuous stimulation of dopaminergic receptors by rotigotine does not interfere with the sleep-wake cycle in the rat.
European journal of pharmacology.
2008 Apr; 584(1):111-7. doi:
10.1016/j.ejphar.2008.01.038. [PMID: 18304531] - C Ruiz-Huete, P E Bermejo, C Terrón, B Anciones. [Rotigotine in the treatment of Parkinson's disease. A study on a sample of 150 patients].
Revista de neurologia.
2008 Mar; 46(5):257-60. doi:
NULL. [PMID: 18351563] - Ubaldo Bonuccelli, Nicola Pavese. Role of dopamine agonists in Parkinson's disease: an update.
Expert review of neurotherapeutics.
2007 Oct; 7(10):1391-9. doi:
10.1586/14737175.7.10.1391. [PMID: 17939774] - Christopher Kenney, Joseph Jankovic. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome.
Expert opinion on pharmacotherapy.
2007 Jun; 8(9):1329-35. doi:
10.1517/14656566.8.9.1329. [PMID: 17563266] - Andrzej Bogucki, Agata Gajos. [Choosing a dopamine agonist in Parkinson's disease].
Neurologia i neurochirurgia polska.
2007 Mar; 41(2 Suppl 1):S14-21. doi:
. [PMID: 17941454] - Sarah Rose, Dieter K A Scheller, Alexander Breidenbach, Lance Smith, Michael Jackson, Kim Stockwell, Peter Jenner. Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates.
Behavioural pharmacology.
2007 Mar; 18(2):155-60. doi:
10.1097/fbp.0b013e3280ebb400. [PMID: 17351422] - Y Naidu, K Ray Chaudhuri. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
Expert opinion on drug delivery.
2007 Mar; 4(2):111-8. doi:
10.1517/17425247.4.2.111. [PMID: 17335409] - Dieter Scheller, Piu Chan, Qin Li, Tao Wu, Renling Zhang, Le Guan, Paula Ravenscroft, Celine Guigoni, Alan R Crossman, Michael Hill, Erwan Bezard. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease.
Experimental neurology.
2007 Feb; 203(2):415-22. doi:
10.1016/j.expneurol.2006.08.026. [PMID: 17045989] - Michele Y Splinter. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
The Annals of pharmacotherapy.
2007 Feb; 41(2):285-95. doi:
10.1345/aph.1h113. [PMID: 17213296] - Willi Cawello, Hans Michael Wolff, Wim J A Meuling, Rolf Horstmann, Marina Braun. Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial.
Clinical pharmacokinetics.
2007; 46(10):851-7. doi:
10.2165/00003088-200746100-00003. [PMID: 17854234] - Joseph Jankovic, Mark Stacy. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
CNS drugs.
2007; 21(8):677-92. doi:
10.2165/00023210-200721080-00005. [PMID: 17630819] - John C Morgan, Kapil D Sethi. Rotigotine for the treatment of Parkinson's disease.
Expert review of neurotherapeutics.
2006 Sep; 6(9):1275-82. doi:
10.1586/14737175.6.9.1275. [PMID: 17009915] - Dag Nyholm. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Clinical pharmacokinetics.
2006; 45(2):109-36. doi:
10.2165/00003088-200645020-00001. [PMID: 16485914] - Grazyna Zareba. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
Drugs of today (Barcelona, Spain : 1998).
2006 Jan; 42(1):21-8. doi:
10.1358/dot.2006.42.1.932510. [PMID: 16511608] - Lorenzo Priano, Maria Rosa Gasco, Alessandro Mauro. Transdermal treatment options for neurological disorders: impact on the elderly.
Drugs & aging.
2006; 23(5):357-75. doi:
10.2165/00002512-200623050-00001. [PMID: 16823990] - L V Metman, M Gillespie, C Farmer, F Bibbiani, S Konitsiotis, M Morris, H Shill, W Bara-Jimenez, M M Mouradian, T N Chase. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
Clinical neuropharmacology.
2001 May; 24(3):163-9. doi:
10.1097/00002826-200105000-00008. [PMID: 11391128] - D R Walters, W R McConnell, E A Cefali. Pharmacokinetic study of (S)-(-)-2-(N-propyl-N-(2-thienylethyl)amino)-5-hydroxytetralin infusion in cynomolgus monkeys.
Journal of pharmaceutical sciences.
1994 May; 83(5):758-60. doi:
10.1002/jps.2600830533. [PMID: 7915310] - P A Zavitsanos, W Siddiqui, M Curtis. A high resolution gas chromatographic/mass spectrometric method for the determination of N-0923 in human and monkey plasma.
Rapid communications in mass spectrometry : RCM.
1993 Dec; 7(12):1145-9. doi:
10.1002/rcm.1290071218. [PMID: 7904195] - P J Swart, R A de Zeeuw. Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats.
Journal of pharmaceutical sciences.
1993 Feb; 82(2):200-3. doi:
10.1002/jps.2600820217. [PMID: 8095299] - P J Swart, R A De Zeeuw. Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats.
Die Pharmazie.
1992 Aug; 47(8):613-5. doi:
NULL. [PMID: 1359583] - S C Ruckmick, B D Hench. Direct analysis of the dopamine agonist (-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin hydrochloride in plasma by high-performance liquid chromatography using two-dimensional column switching.
Journal of chromatography.
1991 Apr; 565(1-2):277-95. doi:
10.1016/0378-4347(91)80390-x. [PMID: 1678747] - R K Sunahara, H C Guan, B F O'Dowd, P Seeman, L G Laurier, G Ng, S R George, J Torchia, H H Van Tol, H B Niznik. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Nature.
1991 Apr; 350(6319):614-9. doi:
10.1038/350614a0. [PMID: 1826762] - J M Jansen, I den Daas, H Rollema, P J Swart, P G Tepper, J B de Vries, A S Horn. Pharmacological profile of non-hydroxylated and ether derivatives of the potent D2-selective agonist N-0437.
Naunyn-Schmiedeberg's archives of pharmacology.
1991 Feb; 343(2):134-42. doi:
10.1007/bf00168600. [PMID: 1676829] - I den Daas, P de Boer, P G Tepper, H Rollema, A S Horn. Orally active carbamate prodrugs of the selective dopamine agonist N-0437: in-vivo activities in the 6-OHDA turning model and in-vitro activities.
The Journal of pharmacy and pharmacology.
1991 Jan; 43(1):11-6. doi:
10.1111/j.2042-7158.1991.tb05439.x. [PMID: 1676052] - T K Gerding, B F Drenth, R A de Zeeuw, P G Tepper, A S Horn. Metabolism and disposition of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in conscious monkeys after subsequent i.v. oral, and ocular administration.
Drug metabolism and disposition: the biological fate of chemicals.
1990 Nov; 18(6):923-8. doi:
NULL. [PMID: 1981538] - T K Gerding, B F Drenth, R A de Zeeuw, A S Horn, J L van Delft, J A Oosterhuis. Ocular and systemic disposition of the dopamine agonist N-0437 in monkeys after ocular administration.
Experimental eye research.
1990 Jul; 51(1):11-4. doi:
10.1016/0014-4835(90)90163-o. [PMID: 1973654] - P J Swart, B F Drenth, R A de Zeeuw. Reversed-phase liquid chromatographic method with amperometric detection for the determination of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0437) in human plasma and urine.
Journal of chromatography.
1990 Jun; 528(2):464-72. doi:
10.1016/s0378-4347(00)82405-6. [PMID: 1974552] - T K Gerding, B F Drenth, H J Roosenstein, R A de Zeeuw, P G Tepper, A S Horn. The metabolic fate of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in rats after intravenous and oral administration. I. Disposition and metabolic profiling.
Xenobiotica; the fate of foreign compounds in biological systems.
1990 May; 20(5):515-24. doi:
10.3109/00498259009046866. [PMID: 1971983] - I den Daas, P G Tepper, A S Horn. Improvement of the oral bioavailability of the selective dopamine agonist N-0437 in rats: the in vitro and in vivo activity of eight ester prodrugs.
Naunyn-Schmiedeberg's archives of pharmacology.
1990 Mar; 341(3):186-91. doi:
10.1007/bf00169729. [PMID: 1971427] - I den Daas, H Rollema, J B de Vries, P G Tepper, A S Horn. Analysis of the dopamine agonist N-0437 in rat serum using reversed-phase high-performance liquid chromatography with electrochemical detection.
Journal of chromatography.
1989 Jan; 487(1):210-4. doi:
10.1016/s0378-4347(00)83027-3. [PMID: 2715268] - K Ensing, D A Bloemhof, W G in 't Hout, J van der Lende, R A de Zeeuw. Development of a radioreceptor assay for the D2-selective dopamine agonist N-0437.
Pharmaceutical research.
1988 May; 5(5):283-7. doi:
10.1023/a:1015922619831. [PMID: 2907622]